Table 4.
Multivariate analysis
|
Overall survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| |
|
Model 1 |
|
|
Model 2 |
|
|
Model 3 |
|
| HR | (95%CI) | p= | HR | (95%CI) | p= | HR | (95%CI) | p= | |
|
PSA,ng/ml |
|
|
|
|
|
|
|
|
|
| ≤10ng/ml |
1.0 |
|
|
1.0 |
|
|
1.0 |
|
|
| >10ng/ml |
0.54 |
(0.15-2.03) |
0.4 |
0.48 |
(0.12-1.86) |
0.3 |
0.48 |
(0.12-1.87) |
0.3 |
|
Extra-prostatic extension | |||||||||
| Yes |
1.0 |
|
|
1.0 |
(0.76-17.35) |
|
1.0 |
|
|
| No |
3.43 |
(0.73-16.12) |
0.1 |
3.63 |
|
0.1 |
3.48 |
(0.73-16.54) |
0.1 |
|
Pelvic nodes involved | |||||||||
| N0 |
1.0 |
|
|
1.0 |
|
|
1.0 |
|
|
| N+ |
1.71 |
(0.50-5.79) |
0.4 |
1.44 |
(0.43-4.83) |
0.5 |
1.40 |
(0.42-4.72) |
0.6 |
|
Surgical margins involved | |||||||||
| No |
1.0 |
|
|
1.0 |
|
|
1.0 |
|
|
| Yes |
1.37 |
(0.45-4.21) |
0.6 |
1.38 |
(0.47-4.01) |
0.6 |
1.33 |
(0.45-3.92) |
0.6 |
|
Seminal vesicles involved | |||||||||
| No |
1.0 |
|
|
1.0 |
|
|
1.0 |
|
|
| Yes |
1.39 |
(0.49-3.94) |
0.5 |
1.08 |
(0.37-3.10) |
0.9 |
1.11 |
(0.38-3.25) |
0.8 |
|
Gleason score | |||||||||
| <7 |
1.0 |
|
|
|
|
|
|
|
|
| ≥7 |
2.13 |
(0.55-8.19) |
0.3 |
|
|
|
|
|
|
|
Gleason score | |||||||||
| ≤7 |
|
|
|
1.0 |
|
|
|
|
|
| >7 |
|
|
|
2.80 |
(0.93-8.47) |
0.07 |
|
|
|
|
Gleason score | |||||||||
| <7 |
|
|
|
|
|
|
1.0 |
|
0.1 |
| =7 |
|
|
|
|
|
|
1.43 |
(0.32-6.40) |
0.6 |
| >7 |
|
|
|
|
|
|
3.52 |
(0.79-15.61) |
0.1 |
|
Epithelial IRS | |||||||||
| >2 |
1.0 |
|
|
1.0 |
|
|
1.0 |
|
|
| ≤2 |
3.22 |
(0.56-18.48) |
0.2 |
3.09 |
(0.51-18.63) |
0.2 |
3.19 |
(0.52-19.47) |
0.2 |
|
Stroma IRS | |||||||||
| <12 |
1.0 |
|
|
1.0 |
|
|
1.0 |
|
|
| =12 | 5.85 | (1.82-18.77) | 0.003 | 5.76 | (1.84-18.07) | 0.003 | 5.99 | (1.87-19.22) | 0.003 |
Abbreviations:HR,Hazard Ratio;CI Confidence Interval;PSA,Prostate-specific antigen;IRS Immuno-reactive score.